Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Diana L Blithe

Showing results (1-10 of 53) with videos related to

Pageof 6
Sort By:
Fertility and Sterility|August 16, 2016
Pipeline for contraceptive developmentDiana L Blithe
Human Reproduction Update|July 17, 2007
Progesterone receptor modulators and the endometrium: changes and consequencesFrances McFarland Horne, Diana L Blithe
Andrology|July 20, 2024
Contraceptive efficacy: Determining the threshold for effective suppression based on sperm concentration, motility, and morphologyChristina Wang, Christopher L R Barratt, Diana L Blithe
Andrology|May 15, 2024
Development of new hormonal male contraception for the coupleJeffrey M Kroopnick, Min S Lee, Diana L Blithe
Clinical Chemistry|January 4, 2019
Male Contraceptive Development: Update on Novel Hormonal and Nonhormonal MethodsJill E Long, Min S Lee, Diana L Blithe
The Journal of Clinical Endocrinology and Metabolism|January 22, 2021
Update on Novel Hormonal and Nonhormonal Male Contraceptive DevelopmentJill E Long, Min S Lee, Diana L Blithe
Contraception|January 25, 2025
Development of a transdermal gel for reversible male contraceptionRegine Sitruk-Ware, Diana L Blithe, Stephanie T Page, et al.
Pharmaceutics|August 29, 2024
Identification of the Biotransformation Pathways of a Potential Oral Male Contraceptive, 11β-Methyl-19-Nortestosterone (11β-MNT) and Its Prodrugs: An In Vitro Study Highlights the Contribution of Polymorphic Intestinal UGT2B17Namrata Bachhav, Dilip Kumar Singh, Diana L Blithe, et al.
Steroids|December 12, 2003
Development of the selective progesterone receptor modulator CDB-2914 for clinical indicationsDiana L Blithe, Lynnette K Nieman, Richard P Blye, et al.
Contraception|August 1, 2016
Levonorgestrel butanoate intramuscular injection does not reliably suppress ovulation for 90 days in obese and normal-BMI women: a pilot studyAlison B Edelman, Ganesh Cherala, Hong Li, et al.
Pageof 6

Showing results (1-10 of 53) with videos related to

Sort By:
Pageof 6
Fertility and Sterility|August 16, 2016
Pipeline for contraceptive developmentDiana L Blithe
Human Reproduction Update|July 17, 2007
Progesterone receptor modulators and the endometrium: changes and consequencesFrances McFarland Horne, Diana L Blithe
Andrology|July 20, 2024
Contraceptive efficacy: Determining the threshold for effective suppression based on sperm concentration, motility, and morphologyChristina Wang, Christopher L R Barratt, Diana L Blithe
Andrology|May 15, 2024
Development of new hormonal male contraception for the coupleJeffrey M Kroopnick, Min S Lee, Diana L Blithe
Clinical Chemistry|January 4, 2019
Male Contraceptive Development: Update on Novel Hormonal and Nonhormonal MethodsJill E Long, Min S Lee, Diana L Blithe
The Journal of Clinical Endocrinology and Metabolism|January 22, 2021
Update on Novel Hormonal and Nonhormonal Male Contraceptive DevelopmentJill E Long, Min S Lee, Diana L Blithe
Contraception|January 25, 2025
Development of a transdermal gel for reversible male contraceptionRegine Sitruk-Ware, Diana L Blithe, Stephanie T Page, et al.
Pharmaceutics|August 29, 2024
Identification of the Biotransformation Pathways of a Potential Oral Male Contraceptive, 11β-Methyl-19-Nortestosterone (11β-MNT) and Its Prodrugs: An In Vitro Study Highlights the Contribution of Polymorphic Intestinal UGT2B17Namrata Bachhav, Dilip Kumar Singh, Diana L Blithe, et al.
Steroids|December 12, 2003
Development of the selective progesterone receptor modulator CDB-2914 for clinical indicationsDiana L Blithe, Lynnette K Nieman, Richard P Blye, et al.
Contraception|August 1, 2016
Levonorgestrel butanoate intramuscular injection does not reliably suppress ovulation for 90 days in obese and normal-BMI women: a pilot studyAlison B Edelman, Ganesh Cherala, Hong Li, et al.
Pageof 6